UA110822C2 - Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів - Google Patents

Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів

Info

Publication number
UA110822C2
UA110822C2 UAA201313012A UAA201313012A UA110822C2 UA 110822 C2 UA110822 C2 UA 110822C2 UA A201313012 A UAA201313012 A UA A201313012A UA A201313012 A UAA201313012 A UA A201313012A UA 110822 C2 UA110822 C2 UA 110822C2
Authority
UA
Ukraine
Prior art keywords
agonists
receptor
monocarboxylic acid
piperidine
piperidine monocarboxylic
Prior art date
Application number
UAA201313012A
Other languages
English (en)
Inventor
Марк Капе
Ізабель Беребі-Бертран
Філіп Робер
Жан-Шарль Шварц
Жан-Марі Лєкомт
Раджаманнар Тхеннаті
Ранджан Кумар Пал
Бісваджіт Саманта
Мутхукумаран Натараджан Піллай
Джапан Нітінкумар Десай
Діджікса Чандубхай Рана
Каушік Джанджубхай Прадждапаті
Сандіп Панкаджбхай Патхак
Бхавеш М. Панчал
Джайрадж Д. Арадхіє
Original Assignee
Біопроже
Сан Фарма Едвансд Рісьоч Компані Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Біопроже, Сан Фарма Едвансд Рісьоч Компані Лтд filed Critical Біопроже
Publication of UA110822C2 publication Critical patent/UA110822C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Даний винахід стосується нових сполук, які діють як агоністи рецепторів S1P (сфінгозин-1-фосфат), композицій, які містять ці сполуки, застосування цих сполук в медицині та способу їх отримання.
UAA201313012A 2011-04-12 2012-10-04 Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів UA110822C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305433A EP2511275A1 (en) 2011-04-12 2011-04-12 Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
PCT/EP2012/056470 WO2012140020A1 (en) 2011-04-12 2012-04-10 Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists

Publications (1)

Publication Number Publication Date
UA110822C2 true UA110822C2 (uk) 2016-02-25

Family

ID=43984071

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201313012A UA110822C2 (uk) 2011-04-12 2012-10-04 Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів

Country Status (25)

Country Link
US (1) US9266867B2 (uk)
EP (2) EP2511275A1 (uk)
JP (1) JP6050315B2 (uk)
KR (1) KR101854152B1 (uk)
CN (1) CN103619838B (uk)
AU (1) AU2012241981B2 (uk)
BR (1) BR112013026434B1 (uk)
CA (1) CA2833180C (uk)
CO (1) CO6801772A2 (uk)
DK (1) DK2697219T3 (uk)
EA (1) EA023638B1 (uk)
EC (1) ECSP13012983A (uk)
ES (1) ES2544616T3 (uk)
HU (1) HUE025443T2 (uk)
IL (1) IL228844A (uk)
MA (1) MA35305B1 (uk)
MX (1) MX342926B (uk)
PH (1) PH12013502142A1 (uk)
PL (1) PL2697219T3 (uk)
PT (1) PT2697219E (uk)
SG (1) SG194183A1 (uk)
TN (1) TN2013000425A1 (uk)
UA (1) UA110822C2 (uk)
WO (1) WO2012140020A1 (uk)
ZA (1) ZA201307820B (uk)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3484880T (pt) * 2016-07-13 2020-12-07 Leo Pharma As Moduladores heteroaromáticos do recetor órfão gama relacionado com retinóide
CN111807954B (zh) * 2019-04-10 2024-04-05 广东东阳光药业股份有限公司 一种辛波莫德中间体的制备方法
US20240228441A1 (en) * 2021-04-14 2024-07-11 Lg Chem, Ltd. Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用
WO2024029638A1 (ko) * 2022-08-01 2024-02-08 한국과학기술연구원 신규한 헤테로사이클릴-페닐-메틸아민 유도체, 이의 제조방법 및 이의 다발성 경화증 예방, 개선, 또는 치료 용도
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
CN117623967A (zh) * 2023-11-16 2024-03-01 迪嘉药业集团股份有限公司 一种替米沙坦中间体3-甲基-4-氨基苯甲酸的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE441654T1 (de) * 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク エンド カムパニー インコーポレーテッド Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
CN101562977A (zh) * 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
EP2014653A1 (en) * 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
EA201070422A1 (ru) * 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
GB0725102D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
CA2745356C (en) * 2008-12-05 2016-12-20 Astellas Pharma Inc. 2h-chromene compound and derivative thereof
EP2305660A1 (en) * 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EP2366702A1 (en) * 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
PT2672823T (pt) * 2011-02-07 2016-11-21 Biogen Ma Inc Agentes que modulam s1p

Also Published As

Publication number Publication date
EP2697219B1 (en) 2015-03-04
EA201301150A1 (ru) 2014-03-31
IL228844A (en) 2016-11-30
WO2012140020A1 (en) 2012-10-18
KR101854152B1 (ko) 2018-05-04
EP2511275A1 (en) 2012-10-17
KR20140041486A (ko) 2014-04-04
JP2014510770A (ja) 2014-05-01
JP6050315B2 (ja) 2016-12-21
DK2697219T3 (en) 2015-06-15
PL2697219T3 (pl) 2015-10-30
IL228844A0 (en) 2013-12-31
ES2544616T3 (es) 2015-09-02
MA35305B1 (fr) 2014-08-01
US20140099316A1 (en) 2014-04-10
SG194183A1 (en) 2013-12-30
NZ617500A (en) 2016-03-31
AU2012241981A1 (en) 2013-10-31
ZA201307820B (en) 2014-11-26
CA2833180C (en) 2021-09-28
PH12013502142A1 (en) 2014-01-13
EP2697219A1 (en) 2014-02-19
CN103619838A (zh) 2014-03-05
US9266867B2 (en) 2016-02-23
BR112013026434B1 (pt) 2021-12-28
TN2013000425A1 (en) 2015-03-30
EA023638B1 (ru) 2016-06-30
CN103619838B (zh) 2016-08-24
ECSP13012983A (es) 2014-05-31
AU2012241981B2 (en) 2016-12-15
MX342926B (es) 2016-10-19
MX2013011984A (es) 2014-06-23
HUE025443T2 (en) 2016-04-28
CO6801772A2 (es) 2013-11-29
BR112013026434A2 (pt) 2016-12-20
CA2833180A1 (en) 2012-10-18
PT2697219E (pt) 2015-07-09

Similar Documents

Publication Publication Date Title
TN2014000254A1 (en) Substituted triazolopyridines and their use as ttk inhibitors
IN2014MN02598A (uk)
GEAP202413811A (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
UA114087C2 (xx) Похідні піридину
PH12015501385A1 (en) Autotaxin inhibitors
UA109010C2 (en) Morpholino pyrividines and their use in therapy
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
EA201590887A1 (ru) Композиция
EA201600366A1 (ru) Производные бензимидазол-пролина
EA201591195A1 (ru) Новые хинолоновые производные
EA201301181A1 (ru) Триазолопиридины
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
EA201490037A1 (ru) Антагонисты trpv4
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
EA201490599A1 (ru) Соединения триазолопиридина в качестве ингибиторов фосфодиэстеразы pde10a
UA111357C2 (uk) Аналоги епоксіейкозатриєнової кислоти, композиція на їх основі, застосування для лікування захворювань та спосіб зниження гіпертонії та нефротоксичності (варіанти)
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
TN2013000425A1 (en) Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists
MX2014002682A (es) Modulares de la fosfodiesterasa 10 (pde 10).
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
CU24360B1 (es) Derivados de ácido heteroaril butanoico como inhibidores de lta4h
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
UA114082C2 (xx) Спосіб одержання водорозчинних селеноглікопротеїнів та композиція, що їх містить